Arcus Biosciences shares rise 7.26% intraday after announcing an Investor Event to highlight new data for its HIF-2a inhibitor casdatifan.

Arcus Biosciences, Inc. rose 7.26% intraday, with the company announcing an upcoming Investor Event on October 6, 2025, to highlight new data for its HIF-2a inhibitor casdatifan from the Phase 1b ARC-20 trial in late-line clear cell renal cell carcinoma (ccRCC). The event will feature presentations from Arcus management and key opinion leaders, and will also discuss the company's research efforts and preclinical programs against autoimmune and inflammatory diseases.